selected publications
-
academic article
-
Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET.
PET Clinics.
12.
2017
Safety, Dosimetry, and Tumor Detection Ability of 68Ga-NOTA-AE105: First-in-Human Study of a Novel Radioligand for uPAR PET Imaging.
Journal of Nuclear Medicine.
58.
2017
Urokinase Plasminogen Activator Receptor–PET with 68Ga-NOTA-AE105 First Clinical Experience with a Novel PET Ligand.
PET Clinics.
12.
2017
Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer.
BMC Cancer.
17.
2017
uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model.
Oncotarget.
5.
2017
C4.4A gene ablation is compatible with normal epidermal development and causes modest overt phenotypes.
Scientific Reports.
6.
2016
PET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectives.
Clinical and Translational Imaging.
4.
2016
Peptide-Based Optical uPAR Imaging for Surgery: In Vivo Testing of ICG-Glu-Glu-AE105.
PLoS ONE.
11.
2016
Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180.
The Journal of Pathology.
238.
2016
Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma.
Journal of Nuclear Medicine.
57.
2016
First-in-human uPAR PET: Imaging of Cancer Aggressiveness.
Theranostics.
5.
2015
Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging.
Nuclear Medicine and Biology.
41.
2014
uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer..
Molecular Pharmaceutics.
11.
2014
-
dataset
-
Plasma stability..
public-library-of-science.
2016
-
hide from search
-
First 18F-labeled ligand for PET imaging of uPAR: In vivo studies in human prostate cancer xenografts.
Nuclear Medicine and Biology.
2013
High tumor uptake of 64Cu: Implications for molecular imaging of tumor characteristics with copper-based PET tracers.
Nuclear Medicine and Biology.
2013
Improved PET Imaging of uPAR Expression Using new64Cu-labeled Cross-Bridged Peptide Ligands: Comparativein vitroandin vivoStudies.
Theranostics.
2013
Urokinase‐type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications.
Clinical Physiology and Functional Imaging.
2013